Apoptosis in polycystic kidney disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 10, 2011, Pages 1272-1280

  Goilav, Béatrice ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Caspases; Cell Cycle; Polycystic kidney disease

Indexed keywords

APOPTOSOME; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BETA GLOBIN; CASPASE; CASPASE 3; CASPASE 8; CASPASE 9; CASPASE INHIBITOR; COLLAGEN TYPE 1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOCHROME C; EVEROLIMUS; FIBROCYSTIN; G PROTEIN COUPLED RECEPTOR; HEAT SHOCK PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLSERINE; POLYCYSTIN 1; POLYCYSTIN 2; PROCASPASE 3; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; RAPAMYCIN; ROSCOVITINE; SHORT HAIRPIN RNA; SURVIVIN; TRANSCRIPTION FACTOR AP 2;

ANGIOMYOLIPOMA; APOPTOSIS; BACULOVIRUS; CANCER THERAPY; CELL ACTIVITY; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DEATH; CELL DIVISION; CELL GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CELL VOLUME; CHROMATIN; CHROMATIN CONDENSATION; CHROMOSOME 16P; CYTOSKELETON; CYTOSOL; DISEASE COURSE; DNA FRAGMENTATION; DNA REPLICATION; DNA SPLICING; DOWN REGULATION; DRUG EFFICACY; DRUG TOLERANCE; EUKARYOTE; FOLLOW UP; FRAGMENTATION REACTION; GENE OVEREXPRESSION; GRAFT REJECTION; HUMAN; IN VITRO STUDY; INFLAMMATION; KIDNEY CANCER; KIDNEY DYSFUNCTION; KIDNEY EPITHELIUM; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; KIDNEY INTERSTITIUM; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; NEOPLASM; NEPHRON; NEPHRONOPHTHISIS; NONHUMAN; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTO ONCOGENE; REMISSION; RETROSPECTIVE STUDY; REVIEW; RNA INTERFERENCE; SIMIAN VIRUS 40; SPLEEN; THYMUS; TUBEROUS SCLEROSIS; UNSPECIFIED SIDE EFFECT; UPREGULATION; UREMIA;

ANIMALS; APOPTOSIS; CASPASES; CELL CYCLE; CYCLIN-DEPENDENT KINASES; HUMANS; MICE; MODELS, STATISTICAL; POLYCYSTIC KIDNEY DISEASES; PROTO-ONCOGENES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRPP CATION CHANNELS;

MURINAE; RODENTIA;

EID: 80052259229     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.01.006     Document Type: Review

References (127)

1. Wilson P.D. Polycystic kidney disease. N. Engl. J. Med. 2004, 350:151-164.
2. Guay-Woodford L., Desmond R. Autosomal recessive polycystic kidney disease (ARPKD): the clinical experience in North America. Pediatrics 2003, 111:1072-1080.
3. Zerres K., Rudnik-Schöneborn S., Senderek J., Eggermann T., Bergmann C. Autosomal recessive polycystic kidney disease (ARPKD). J. Nephrol. 2003, 16:453-458.
4. Menezes L.F., Cai Y., Nagasawa Y., Silva A.M., Watkins M.L., Da Silva A.M., Somlo S., Guay-Woodford L.M., Germino G.G., Onuchic L.F. Polyductin, the PKHD1 gene product, comprises isoforms expressed in plasma membrane, primary cilium, and cytoplasm. Kidney Int. 2004, 66:1345-1355.
5. Goilav B., Norton K.I., Satlin L.M., Guay-Woodford L., Chen F., Magid M.S., Emre S., Shneider B.L. Predominant extrahepatic biliary disease in autosomal recessive polycystic kidney disease: a new association. Pediatr. Transplant 2006, 10:294-298.
6. Wilson P.D., Goilav B. Cystic disease of the kidney. Annu. Rev. Pathol. 2007, 2:341-368.
7. Kuure S., Vuolteenaho R., Vainio S. Kidney morphogenesis: cellular and molecular regulation. Mech. Dev. 2000, 92:31-45.
8. Woo D. Apoptosis and loss of renal tissue in polycystic kidney diseases. N. Engl. J. Med. 1995, 333:18-25.
9. Kip S.N., Hunter L.W., Ren Q., Harris P.C., Somlo S., Torres V.E., Sieck G.C., Qian Q. [Ca2+]i reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells: relevance to the ADPKD phenotype. Circ. Res. 2005, 96:873-880.
10. Bukanov N.O., Smith L.A., Klinger K.W., Ledbetter S.R., Ibraghimov-Beskrovnaya O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 2006, 444:949-952.
11. Starremans P.G., Li X., Finnerty P.E., Guo L., Takakura A., Neilson E.G., Zhou J. A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5' end of Pkd1. Kidney Int. 2008, 73:1394-1405.
12. Goilav B., Satlin L.M., Wilson P.D. Pathways od apoptosis in human autosomal recessive and autosomal dominant polycystic kidney diseases. Pediatr. Nephrol. 2008, 23:1473-1482.
13. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26:239-257.
14. Ren Y., Savill J. Apoptosis: the importance of being eaten. Cell Death Differ. 1998, 5:563-568.
15. Cohen J. Death and the danse macabre. Hist. Today 1982, 32:35-40.
16. Fadeel B., Xue D., Kagan V. Programmed cell clearance: molecular regulation of the elimination of apoptotic cell corpses and its role in the resolution of inflammation. Biochem. Biophys. Res. Commun. 2010, 396:7-10.
17. Green D.R. Apoptotic pathways: paper wraps stone blunts scissors. Cell 2000, 102:1-4.
18. Wolf B.B., Green D.R. Suicidal tendencies: apoptotic cell death by caspase family proteinases. J. Biol. Chem. 1999, 274:20049-20052.
19. Green D.R. Apoptotic pathways: the roads to ruin. Cell 1998, 94:695-698.
20. Barinaga M. Cell suicide: by ICE, not fire. Science 1994, 263:754-756.
21. Salvesen G.S., Dixit V.M. Caspases: intracellular signaling by proteolysis. Cell 1997, 91:443-446.
22. Fraser A., Evan G. A license to kill. Cell 1996, 85:781-784.
23. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995, 376:37-43.
24. Deveraux Q.L., Reed J.C. IAP family proteins-suppressors of apoptosis. Genes Dev. 1999, 13:239-252.
25. Miller L.K. An exegesis of IAPs: salvation and surprises from BIR motifs. Trends Cell Biol. 1999, 9:323-328.
26. Srinivasula S.M., Ashwell J.D. IAPs: what's in a name?. Mol. Cell 2008, 30:123-135.
27. LaCasse E.C., Baird S., Korneluk R.G., MacKenzie A.E. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998, 17:3247-3259.
28. Deveraux Q.L., Leo E., Stennicke H.R., Welsh K., Salvesen G.S., Reed J.C. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999, 18:5242-5251.
29. Verdecia M.A., Huang H., Dutil E., Kaiser D.A., Hunter T., Noel J.P. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat. Struct. Biol. 2000, 7:602-608.
30. Li F. Survivin study: what is the next wave?. J. Cell. Physiol. 2003, 197:8-29.
31. Garrido C., Gurbuxani S., Ravagnan L., Kroemer G. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem. Biophys. Res. Commun. 2001, 286:433-442.
32. Martin S.J. Destabilizing influences in apoptosis: sowing the seeds of IAP destruction. Cell 2002, 109:793-796.
33. Kvansakul M., Yang H., Fairlie W.D., Czabotar P.E., Fischer S.F., Perugini M.A., Huang D.C., Colman P.M. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death Differ. 2008, 15:1564-1571.
34. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998, 281:1322-1326.
35. Korsmeyer S.J. BCL-2 gene family and the regulation of programmed cell death. Cancer Res. 1999, 59:1693s-1700s.
36. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science 1998, 281:1305-1308.
37. Darzynkiewicz Z., Bruno S., Del Bino G., Gorczyca W., Hotz M.A., Lassota P., Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry 1992, 13:795-808.
38. Kaufmann S.H., Mesner P.W., Samejima K., Tone S., Earnshaw W.C. Detection of DNA cleavage in apoptotic cells. Methods Enzymol. 2000, 322:3-15.
39. Fadok V.A., Bratton D.L., Frasch S.C., Warner M.L., Henson P.M. The role of phosphatidylserine in recognition of apoptotic cells by phagocytes. Cell Death Differ. 1998, 5:551-562.
40. Koopman G., Reutenlingsperger C.P.M., Kuijten G.A.M., Keehnen R.M.J., Pals S.T., van Oers M.H.J. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994, 84:1415-1420.
41. Van Loo G., Saelens X., van Gurp M., MacFarlane M., Martin S.J., Vandenabeele P. The role of mitochondrial factors in apoptosis: a Russian roulette with more than one bullet. Cell Death Differ. 2002, 10:1031-1042.
42. Poot M., Pierce R.H. Detection of changes in mitochondrial function during apoptosis by simultaneous staining with multiple fluorescent dyes and correlated multiparameter flow cytometry. Cytometry 1999, 35:311-317.
43. Murcia N.S., Sweeney W.E., Avner E.D. New insights into the molecular pathophysiology of polycystic kidney disease. Kidney Int. 1999, 55:1187-1197.
44. Lanoix J., D'Agati V., Szabolcs M., Trudel M. Dysregulation of cellular proliferation and apoptosis mediates human autosomal dominant polycystic kidney disease. Oncogene 1996, 13:1153-1160.
45. Trudel M., D'Agati V., Constantini F. c-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int. 1991, 39:665-671.
46. Veis D.J., Sorenson C.M., Shutter J.R., Korsmeyer S.J. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 1993, 75:229-240.
47. Trudel M., Lanoix J., Barisoni L., Blouin M.J., Desforges M., L'Italien C., D'Agati V.D. C-MYC-induced apoptosis in polycystic kidney disease is Bcl-2 and p53 independent. J. Exp. Med. 1997, 186:1873-1884.
48. Trudel M., Barisoni L., Lanoix J., D'Agati V. Polycystic kidney disease in SBM transgenic mice: role of c-myc in disease induction and progression. Am. J. Pathol. 1998, 152:219-229.
49. Schäfer K., Gretz N., Bader M., Oberbäumer I., Eckardt K.U., Kriz W., Bachmann S. Characterization of the Han:SPRD rat model for hereditary polycystic kidney disease. Kidney Int. 1994, 46:134-152.
50. Kaspareit-Rittinghausen J., Deerberg F., Wcislo A. Hereditary polycystic kidney disease: adult polycystic kidney disease associated with renal hypertension, renal osteodystrophy, and uremic enteritis in SPRD rats. Am. J. Pathol. 1991, 139:693-696.
51. Cowley B.D., Gudapaty S., Kraybill A.L., Barash B.D., Harding M.A., Clavet J.P., Gattone V.H. Autosomal dominant polycystic kidney disease in the rat. Kidney Int. 1993, 43:522-534.
52. Schäfer K., Bader M., Gretz N., Oberbäumer I., Bachmann S. Focal overexpression of collagen IV characterizes the initiation of epithelial changes in polycystic kidney disease. Exp. Nephrol. 1994, 2:190-195.
53. Ogborn M.R., Bankovic-Calic N., Shoesmith C., Buist R., Peeling J. Soy protein modification of rat polycystic kidney disease. Am. J. Physiol. 1998, 274:F541-F549.
54. Zhou X.J., Kukes G. Pathogenesis of autosomal dominant polycystic kidney disease: Role of apoptosis. Diagn. Mol. Pathol. 1998, 7:65-68.
55. Hains D.S., Bates C.M., Ingraham S., Schwaderer A.L. Management and etiology of the unilateral multicystic dysplastic kidney: a review. Pediatr. Nephrol. 2009, 24:233-241.
56. Ecder T., Melnikov V.Y., Stanley M., Korular D., Lucia M.S., Schrier R.W., Edelstein C.L. Caspases, Bcl-2 proteins and apoptosis in autosomal dominant polycystic kidney disease. Kidney Int. 2002, 61:1220-1230.
57. Grantham J.J. Polycystic kidney disease: neoplasia in disguise. Am. J. Kidney Dis. 1990, 15:110-116.
58. Evan G.I., Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-348.
59. McDonnell T.J., Deane N., Platt F.M., Nunez G., Jaeger U., McKearn J.P., Korsmeyer S.J. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989, 7:79-88.
60. Vaux D.L., Cory S., Adams J.M. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988, 335:440-442.
61. Sorenson C.M., Padanilam B.J., Hammerman M.R. Abnormal postpartum renal development and cystogenesis in the bcl-2 (-/-) mouse. Am. J. Physiol. 1996, 271:F184-F193.
62. Fedorov L.M., Schmittwolf C., Amann K., Thomas W.H., Müller A.M., Schubert H., Domen J., Kneitz B. Renal failure causes early death of bcl-2 deficient mice. Mech. Ageing Dev. 2006, 127:600-609.
63. Lin H.H., Yang T.P., Jiang S.T., Yang H.Y., Tang M.J. Bcl-2 over-expression prevents apoptosis-induced Madin-Darby canine kidney simple epithelial cyst formation. Kidney Int. 1999, 55:168-178.
64. Freeman C.L., Harding J.H., Quigley D., Rodger P.M. Structural control of crystal nuclei by an eggshell protein. Angew. Chem. Int. Ed. 2010, 49:5135-5137.
65. Winyard P.J., Nauta J., Lirenman D.S., Hardman P., Sams V.R., Risdon R.A., Woolf A.S. Deregulation of cell survival in cystic and dysplastic renal development. Kidney Int. 1996, 49:135-146.
66. Lager D.J., Qian Q., Bengal R.J., Ishibashi M., Torres V.E. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int. 2001, 59:126-136.
67. Edelstein C.L. What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)?. Cell Cycle 2005, 4:e141-e145.
68. Tao Y., Kim J., Faubel S., Wu J.C., Falk S.A., Schrier R.W., Edelstein C.L. Caspase inhibition reduces tubular apoptosis and proliferation and slows disease progression in polycystic kidney disease. Proc. Natl Acad. Sci. USA 2005, 102:6954-6959.
69. Moser M., Pscherer A., Roth C., Becker J., Mucher G., Zerres K., Dixkens C., Weis J., Guay-Woodford L., Buettner R., Fassler R. Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. Genes Dev. 1997, 11:1938-1948.
70. Boletta A., Qian F., Onuchic L.F., Bhunia A.K., Phakdeekitcharoen B., Hanaoka K., Guggino W., Monaco L., Germino G.G. Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells. Mol. Cell 2000, 6:1267-1273.
71. Nakayama K., Nakayama K., Negishi I., Kuida K., Sawa H., Loh D.Y. Targeted disruption of Bcl-2 alpha beta in mice: occurrence of gray hair, polycystic kidney disease, and lymphocytopenia. Proc. Natl Acad. Sci. USA 1994, 91:3700-3704.
72. Kamada S., Shimono A., Shinto Y., Tsujimura T., Takahashi T., Noda T., Kitamura Y., Kondoh H., Tsujimoto Y. Bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res. 1995, 55:354-359.
73. Wodarczyk C., Distefano G., Rowe I., Gaetani M., Bricoli B., Muorah M., Spitaleri A., Mannella V., Ricchiuto P., Pema M., Castelli M., Casanova A.E., Mollica L., Banzi M., Boca M., Antignac C., Saunier S., Musco G., Boletta A. Nephrocystin-1 forms a complex with polycystin-1 via a polyproline motif/sh3 domain interaction and regulates the apoptotic response in mammals. PLoS ONE 2010, 5:e12719.
74. Yu W., Kong T., Beaudry S., Tran M., Negoro H., Yanamadala V., Denker B.M. Polycystin-1 protein level determines activity of the Galpha12/JNK apoptosis pathway. J. Biol. Chem. 2010, 285:10243-10251.
75. Yu W., Ritchie B.J., Su X., Zhou J., Meigs T.E., Denker B.M. Identification of polycystin-1 and Gα12 binding regions necessary for regulation of apoptosis. Cell. Signal. 2011, 23:213-221.
76. Stroope A., Radtke B., Huang B., Masyuk T., Torres V., Ritman E., LaRusso N. Hepato-renal pathology in pkd2ws25/- mice, an animal model of autosomal dominant polycystic kidney disease. Am. J. Pathol. 2010, 176:1282-1291.
77. Mai W., Chen D., Ding T., Kim I., Park S., Cho S.Y., Chu J.S., Liang D., Wang N., Wu D., Li S., Zhao P., Zent R., Wu G. Inhibition of Pkhd1 impairs tubulomorphogenesis of cultured IMCD cells. Mol. Biol. Cell 2005, 16:4398-4409.
78. Shen H.M., Tergaonkar V. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis 2009, 14:348-363.
79. Grimm S., Bauer M.K., Baeuerle P.A., Schulze-Osthoff K. Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis. J. Cell Biol. 1996, 134:13-23.
80. Mangolini A., Bogo M., Durante C., Borgatti M., Gambari R., Harris P.C., Rizzuto R., Pinton P., Aguiari G., del Senno L. NF-kappaB activation is required for apoptosis in fibrocystin/polyductin-depleted kidney epithelial cells. Apoptosis 2010, 15:94-104.
81. Woo D.D., Miao S.Y., Pelayo J.C., Woolf A.S. Taxol inhibits progression of congenital polycystic kidney disease. Nature 1994, 368:750-753.
82. Ali S.M., Wong V.Y., Kikly K., Fredrickson T.A., Keller P.M., DeWolf W.E., Lee D., Brooks D.P. Apoptosis in polycystic kidney disease: involvement of caspases. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2000, 278:R763-R769.
83. Tao Y., Kim J., Stanley M., He Z., Faubel S., Schrier R.W., Edelstein C.L. Pathways of caspase-mediated apoptosis in autosomal dominant polycystic kidney disease (ADPKD). Kidney Int. 2004, 67:909-919.
84. Tao Y., Zafar I., Kim J., Schrier R.W., Edelstein C.L. Caspase-3 gene deletion prolongs survival in polycystic kidney disease. J. Am. Soc. Nephrol. 2008, 19:749-755.
85. Goilav B., Wilson P.D. Localization and timing of c-FLIP expression in human autosomal dominant polycystic kidney disease: a mirror image of caspase-8 expression 2008.
86. Cowley B.D., Chadwick L.J., Grantham J.J., Calvet J.P. Elevated c-myc proto-oncogene expression in autosomal recessive polycystic kidney disease. Proc. Natl Acad. Sci. USA 1987, 84:8394-8398.
87. Cowley B.D., Chadwick L.J., Grantham J.J., Calvet J.P. Elevated proto-oncogene expression in polycystic kidneys of the C57BL/6J (cpk) mouse. J. Am. Soc. Nephrol. 1991, 1:1048-1053.
88. Trudel M., Agati V.D., Costantini F. C-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int. 1991, 39:665-671.
89. Ricker J.L., Mata J.E., Iversen P.L., Gattone V.H. c-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney Int. 2002, 61:125-131.
90. Soengas M.S., Alarcon R.M., Yoshida H., Giaccia A.J., Hakem R., Mak T.W., Lowe S.W. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science 1999, 284:156-159.
91. Nigg E.A. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays 1995, 17:471-480.
92. Spellman P.T., Sherlock G., Zhang M.Q., Iyer V.R., Anders K., Eisen M.B., Brown P.O., Botstein D., Futcher B. Comprehensive identification of cell cycle-regulated genes of the yeast Saccharomyces cerevisiae by microarray hybridization. Mol. Biol. Cell 1998, 9:3273-3297.
93. Suryadinata R., Sadowski M., Sarcevic B. Control of cell cycle progression by phosphorylation of cyclin-dependent kinase (CDK) substrates. Biosci. Rep. 2010, 30:243-255.
94. Fisher R.P. Coming full circle: cyclin-dependent kinasese as anti-cancer drug targets. Subcell. Biochem. 2010, 50:1-15.
95. Bhunia A.K., Piontek K., Boletta A., Liu L., Qian F., Xu P.N., Germino F.J., Germino G.G. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 2002, 109:157-168.
96. Park J.Y., Schutzer W.E., Lindsley J.N., Bagby S.P., Oyama T.T., Anderson S., Weiss R.H. p21 is decreased in polycystic kidney disease and leads to increased epithelial cell cycle progression: roscovitine augments p21 levels. BMC Nephrol. 2007, 8:12-22.
97. Fingar D.C., Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004, 23:3151-3171.
98. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
99. Edelstein C.L. Mammalian target of rapamycin and caspase inhibitors in polycystic kidney disease. Clin. J. Am. Soc. Nephrol. 2008, 3:1219-1226.
100. Habib S.L. Tuberous sclerosis complex and DNA repair. Adv. Exp. Med. Biol. 2010, 685:84-94.
101. Shillingford J.M., Murcia N.S., Larson C.H., Low S.H., Hedgepeth R., Brown N., Flask C.A., Novick A.C., Goldfarb D.A., Kramer-Zucker A., Walz G., Piontek K.B., Germino G.G., Weimbs T. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci. USA 2006, 103:5466-5471.
102. Shillingford J.M., Piontek K.B., Germino G.G., Weimbs T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J. Am. Soc. Nephrol. 2010, 3:489-497.
103. Wahl P.R., Serra A.L., Le Hir M., Molle K.D., Hall M.N., Wuthrich R.P. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol. Dial. Transplant. 2006, 21:598-604.
104. Wu M., Wahl P.R., Le Hir M., Wackerle-Men Y., Wuthrich R.P., Serra A.L. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press. Res. 2007, 30:253-259.
105. Baba M., Furihata M., Hong S.B., Tessarollo L., Haines D.C., Southon E., Patel V., Igarashi P., Alvord W.G., Leighty R., Yao M., Bernardo M., Ileva L., Choyke P., Warren M.B., Zbar B., Linehan W.M., Schmidt L.S. Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys. J. Natl Cancer Inst. 2008, 100:140-154.
106. Qian Q., Du H., King B.F., Kumar S., Dean P.G., Cosio F.G., Torres V.E. Sirolimus reduces polycystic liver volume in ADPKD patients. J. Am. Soc. Nephrol. 2008, 19:631-638.
107. Walz G., Budde K., Mannaa M., Nürnberger J., Wanner C., Sommerer C., Kunzendorf U., Banas B., Hörl W.H., Obermüller N., Arns W., Pavenstädt H., Gaedeke J., Büchert M., May C., Gschaidmeier H., Kramer S., Eckardt K.U. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2010, 363:830-840.
108. Serra A.L., Poster D., Kistler A.D., Krauer F., Raina S., Young J., Rentsch K.M., Spanaus K.S., Senn O., Kristanto P., Scheffel H., Weishaupt D., Wüthrich R.P. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2010, 363:820-829.
109. Weiss R.H. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003, 4:425-429.
110. Asada M., Yamada T., Ichijo H., Delia D., Miyazono K., Fukumuro K., Mizutani S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18:1223-1234.
111. Fan Y., Borowsky A.D., Weiss R.H. An antisense oligodeoxynucleotide to p21(Waf1/ Cip1) causes apoptosis in human breast cancer cells. Mol. Cancer Ther. 2003, 2:773-782.
112. Sharma R.R., Ravikumar T.S., Raimo D., Yang W.L. Induction of p21(WAF1) expression protects HT29 colon cancer cells from apoptosis induced by cryoinjury. Ann. Surg. Oncol. 2005, 12:743-752.
113. Park J.Y., Park S.H., Weiss R.H. Disparate effects of roscovitine on renal tubular epithelial cell apoptosis and senescence: implications for autosomal dominant polycystic kidney disease. Am. J. Nephrol. 2009, 29:509-515.
114. Han Z., Wei W., Dunaway S., Darnowski J.W., Calabresi P., Sedivy J., Hendrickson E.A., Balan K.V., Pantazis P., Wyche J.H. Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin. J. Biol. Chem. 2002, 277:17154-17160.
115. Herbig U., Jobling W.A., Chen B.P., Chen D.J., Sedivy J.M. Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21(CIP1), but not p16(INK4a). Mol. Cell 2004, 14:501-513.
116. Van Nguyen T., Puebla-Osorio N., Pang H., Dujka M.E., Zhu C. DNA damage-induced cellular senescence is sufficient to suppress tumorigenesis: a mouse model. J. Exp. Med. 2007, 204:1453-1461.
117. Brown J.P., Wei W., Sedivy J.M. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997, 277:831-834.
118. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl Acad. Sci. USA 1995, 92:9363-9367.
119. Feng Z., Zhang H., Levine A.J., Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proc. Natl Acad. Sci. 2005, 102:8204-8209.
120. Torres V.E. Apoptosis in cystogenesis: hands on or hands off?. Kidney Int. 1999, 55:334-335.
121. Wilson P.D., Devuyst O., Li X., Gatti L., Falkenstein D., Robinson S., Fambrough D., Burrow C.R. Apical plasma membrane mispolarization of NaK-ATPase in polycystic kidney disease epithelia is associated with aberrant expression of the b2 isoform. Am. J. Pathol. 2000, 156:253-268.
122. Sorenson C.M. Interaction of bcl-2 with Paxillin through its BH4 domain is important during ureteric bud branching. J. Biol. Chem. 2004, 279:11368-11374.
123. Wilson P.D. Aberrant epithelial cell growth in autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 1991, 17:634-637.
124. Ogborn M.R., Sareen S. Transforming growth factor alpha and epidermal growth factor expression in experimental murine polycystic kidney disease. Pediatr. Nephrol. 1996, 10:181-184.
125. Liu K.D., Brakeman P.R. Renal repair and recovery. Crit. Care Med. 2008, 36:S187-S192.
126. Calvet J.P. Injury and development in polycystic kidney disease. Curr. Opin. Nephrol. Hypertens. 1994, 3:340-348.
127. Chen C.S., Mrksich H., Huang S., Whitesides G.M., Ingber D.E. Geometric control of cell life and death. Science 1997, 276:1425-1429.